ADAPT: transforming precision oncology

We are honored to collaborate with an extraordinary team of scientists on transformative projects aimed at revolutionizing cancer care as a part of ARPA-H’s Advanced Analysis for Precision Cancer Therapy (ADAPT) program. This up to $142 million initiative brings together the nation’s top expertise in tumor biology and cutting-edge technologies to deliver customized cancer care that evolves with each patient’s disease.

Our team, together with Dr. Ravi Salgia, MD, PhD and Dr. Jyoti Malhotra, MD, will lead a groundbreaking initiative by City of Hope—a six-year clinical trial enrolling 535 patients that will serve as the cornerstone of this effort. Read more about the IMMUNO-BIOMAP trial here.

Our lab will also contribute to the development and real-time implementation of multimodal biomarkers within innovative clinical trial frameworks, paving the way for more precise, adaptive, and patient-centered oncology. This ambitious project brings together a powerhouse of collaborators led by Prof. Trey Ideker (UCSD). Read more about the “Digital Tumors for Precision Oncology” project here.

We are proud to be part of a movement that is not only advancing science but also reshaping the future of cancer treatment.